Iproclozide
Chemical compound
- N06AF06 (WHO)
- 2-(4-chlorophenoxy)-N-isopropyl-acetohydrazide
- 3544-35-2 Y
- 19063
- 17998 Y
- 1II9D6CB3J
- D07338 Y
- ChEMBL91238 Y
- DTXSID70188925
- Interactive image
- Clc1ccc(OCC(=O)NNC(C)C)cc1
InChI
- InChI=1S/C11H15ClN2O2/c1-8(2)13-14-11(15)7-16-10-5-3-9(12)4-6-10/h3-6,8,13H,7H2,1-2H3,(H,14,15) Y
- Key:GGECDTUJZOXAAR-UHFFFAOYSA-N Y
Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[2] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[3][4]
See also
- Hydrazine (antidepressant)
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Suerinck A, Suerinck E (April 1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de Médecine de Lyon. 47 (96): 573–586. PMID 5930723.
- ^ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (September 1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. doi:10.1016/0016-5085(78)90856-9. PMID 680506.
- ^ Kaplowitz N, DeLeve LD (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3.
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e